A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection

Publication | Open Access

DOI Full Paper Access

Citations

References

2023

Year

Anna Nilsson, John Pullman, Piotr Napora, Kléber Giovanni Luz, Anil Kumar Gupta, Jorge Draghi, Ana Karla Guzman Romero, Naresh Aggarwal, Galina Petrova, Juliana Ianus,

Clinical Microbiology and Infection

Antiviral ActivityAntiviral Drug DevelopmentAntiviral TherapyVirologyClinical OutcomesPilot Phase 2AChronic Viral InfectionInfection ControlAntiviral DrugMedicine